Amicus Therapeutics Raises FY24 Sales Outlook From $499.195M-$519.163M To $503.19M-$523.16M vs $510.32M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics has raised its FY24 sales outlook, with total revenue now expected to grow between 26% to 31%, and Galafold revenue growth adjusted to 14% to 18%. The updated sales outlook is $503.19M-$523.16M, compared to the previous estimate of $499.195M-$519.163M.
August 08, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amicus Therapeutics has raised its FY24 sales outlook, with total revenue now expected to grow between 26% to 31%, and Galafold revenue growth adjusted to 14% to 18%. The updated sales outlook is $503.19M-$523.16M, compared to the previous estimate of $499.195M-$519.163M.
The raised sales outlook and improved revenue growth projections are positive indicators for Amicus Therapeutics, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100